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ILLUSTRATIVE CASE
Mrs. D is a 45-year-old patient whom you’ve 
treated for type 2 diabetes for several years. 
On her latest visit, she reports a loss of 
energy and diffi culty sleeping and wonders 
if they could be related to the diabetes. As 
you explore further and question Mrs. D 
about these symptoms, she becomes 
tearful—and tells you she has episodes of 
sadness and no longer enjoys things the 
way she used to. Although she has no past 
history of depression, when you suggest 
that her symptoms may be an indication of 
depression, she readily agrees. 
You discuss treatment options, includ-
ing antidepressants and therapy. Mrs. D 
decides to try medication. But with so many 
antidepressants on the market, how do you 
determine which to choose?
Major depression is the fourth leading cause of disease globally, according to the World Health 
Organization.2 Depression is common 
in the United States as well, and primary 
care physicians are often the ones who 
are diagnosing and treating it. In fact, 
the US Preventive Services Task Force re-
cently expanded its recommendation that 
primary care providers screen adults for 
depression, to include adolescents ages 
12 to 18 years.3 When depression is di-
agnosed, physicians must help patients 
decide on an initial treatment plan. 
❚  All antidepressants 
are not equal
Options for initial treatment of unipolar 
major depression include psychotherapy 
and the use of an antidepressant. For mild 
and moderate depression, psychotherapy 
alone is as effective as medication. Com-
bined psychotherapy and antidepressants 
are more effective than either treatment 
alone for all degrees of depression.4
When you initiate antidepres-
sant therapy for patients who 
have not been treated for 
depression previously, select 
either sertraline or escitalo-
pram. A large meta-analysis 
found these medications to 
be superior to other “new-
generation” antidepressants.1 
Strength of recommendation 
A: Meta-analysis of 117 high-quality studies. 
Cipriani A, Furukawa TA, Salanti G, et al. 
Comparative effi cacy and acceptability of 12 new-
generation antidepressants: a multiple-treatments 
meta-analysis. Lancet. 2009;373:746-758.
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What factors into 
your choice of 
antidepressant when 
initiating therapy? 
❑  Side-effect proﬁ le. 
❑  Cost; whenever possible, 
I prescribe a generic. 
❑  Patient preference, 
side-effect proﬁ le, and 
cost get equal weight.
❑  Past experience; I 
prescribe based on 
the success of other 
patients in my practice.
❑  Other ______________
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The ideal medication for depression 
would be a drug with a high level of ef-
fectiveness and a low side-effect profi le; 
until now, however, there has been little 
evidence to support 1 antidepressant 
over another. Previous meta-analyses 
have concluded that there are no sig-
nifi cant differences in either effi cacy or 
acceptability among the various second- 
generation antidepressants on the mar-
ket.5,6 Thus, physicians have historically 
made initial monotherapy treatment de-
cisions based on side effects and cost.7,8
The meta-analysis we report on here 
tells a different story, providing strong 
evidence that some antidepressants are 
more effective and better tolerated than 
others.
STUDY SUMMARY
❚ Meta-analysis reveals 
2 “best” drugs
Cipriani et al1 conducted a systematic 
review and multiple-treatments meta-
analysis of 117 prospective randomized 
controlled trials (RCTs). Taken together, 
the RCTs evaluated the comparative 
effi cacy and acceptability of 12 second-
generation antidepressants: bupropion, 
citalopram, duloxetine, escitalopram, 
fl uoxetine, fl uvoxamine, milnacipran, 
mirtazapine, paroxetine, reboxetine, 
sertraline, and venlafaxine. The meth-
odology of this meta-analysis differed 
from that of traditional meta-analyses 
by allowing the integration of data 
from both direct and indirect compari-
sons. (An indirect comparison is one in 
which drugs from different trials are 
assessed by combining the results of 
their effectiveness and comparing the 
combined fi nding with the effective-
ness of a drug that all the trials have 
in common.) Previous studies, based 
only on direct comparisons, yielded 
inconsistent results.
The studies included in this meta-
analysis were all RCTs in which 1 of 
these 12 antidepressants was tested 
against 1, or several, other second-gen-
eration antidepressants as monotherapy 
for the acute treatment phase of unipo-
lar major depression. The authors ex-
cluded placebo-controlled trials in order 
to evaluate effi cacy and acceptability of 
the study medications relative to other 
commonly used antidepressants. They 
defi ned acute treatment as 8 weeks of 
antidepressant therapy, with a range of 
6 to 12 weeks. The primary outcomes 
studied were response to treatment and 
dropout rate. 
Response to treatment (effi cacy) was 
constructed as a Yes or No variable; a 
positive response was defi ned as a re-
duction of ≥50% in symptom score on 
either the Hamilton depression rating 
scale or the Montgomery-Asberg rat-
ing scale, or a rating of “improved” or 
“very much improved” on the clinical 
global impression at 8 weeks. Effi cacy 
was calculated on an intention-to-treat 
basis; if data were missing for a par-
ticipant, that person was classifi ed as a 
nonresponder. 
Dropout rate was used to represent 
acceptability, as the authors believed 
it to be a more clinically meaning-
Using fl uoxetine as the reference medication, the researchers analyzed 
various second-generation antidepressants. Sertraline and escitalopram 
had the best combination of effi cacy and acceptability. 
OR, odds ratio. 
Source: Cipriani A et al. Lancet. 2009.1
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PURLs methodology
This study was selected and 
evaluated using FPIN’s Priority 
Updates from the Research 
Literature (PURL) Surveillance 
System methodology. The 
criteria and ﬁ ndings leading to 
the selection of this study as 
a PURL can be accessed at 
www.jfponline.com/purls. 
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ful measure than either side effects or 
symptom scores. Comparative effi cacy 
and acceptability were analyzed. Fluox-
etine—the fi rst of the second-generation 
antidepressants—was used as the refer-
ence medication. The FIGURE shows the 
outcomes for 9 of the antidepressants, 
compared with those of fl uoxetine. The 
other 2 antidepressants, milnacipran 
and reboxetine, are omitted because 
they are not available in the United 
States. 
The overall meta-analysis included 
25,928 individuals, with 24,595 in the 
effi cacy analysis and 24,693 in the ac-
ceptability analysis. Nearly two-thirds 
(64%) of the participants were women. 
The mean duration of follow-up was 
8.1 weeks, and mean sample size per 
study was 110. Studies of women with 
postpartum depression were excluded.
Escitalopram and sertraline stand 
out. Overall, escitalopram, mirtazapine, 
sertraline, and venlafaxine were signifi -
cantly more effi cacious than fl uoxetine 
or the other medications. Bupropion, 
citalopram, escitalopram, and sertraline 
were better tolerated than the other anti-
depressants. Escitalopram and sertraline 
were found to have the best combination 
of effi cacy and acceptability. 
Efﬁ cacy results. Fifty-nine percent of 
participants responded to sertraline, vs a 
52% response rate for fl uoxetine (num-
ber needed to treat [NNT]=14). Similarly, 
52% of participants responded to esci-
talopram, compared with 47% of those 
taking fl uoxetine (NNT=20). 
Acceptability results. In terms of drop-
out rate, 28% of participants discontin-
ued fl uoxetine, vs 24% of patients taking 
sertraline. This means that 25 patients 
would need to be treated with sertraline, 
rather than fl uoxetine, to avoid 1 discon-
tinuation. In the comparison of fl uoxetine 
vs escitalopram, 25% discontinued fl uox-
etine, compared with 24% who discon-
tinued escitalopram. 
The effi cacy  and  acceptability of 
sertraline and escitalopram compared 
with other second-generation anti-
depressant medications show similar 
trends. 
The generic advantage. The investi-
gators recommend sertraline as the best 
choice for an initial antidepressant be-
cause it is available in generic form and 
is therefore lower in cost. They further 
recommend that sertraline, instead of 
fl uoxetine or placebo, be the new stan-
dard against which other antidepressants 
are compared. 
WHAT’S NEW?
❚  Antidepressant choice 
is evidence-based 
We now have solid evidence for choos-
ing sertraline or escitalopram as the 
fi rst medication to use when treating a 
patient with newly diagnosed depres-
sion. This represents a practice change 
because antidepressants that are less 
effective and less acceptable have been 
chosen more frequently than either of 
these medications. That conclusion is 
based on our analysis of the National 
Ambulatory Medical Care Survey data-
base for outpatient and ambulatory clin-
ic visits in 2005-2006 (the most recent 
data available). We conducted this anal-
ysis to determine which of the second-
generation antidepressants were pre-
scribed most for initial monotherapy 
of major depression. 
Our fi nding: An estimated 4 million 
patients ages 18 years and older diag-
nosed with depression in the course of 
the study year received new prescrip-
tions for a single antidepressant. Six 
medications accounted for 90% of the 
prescriptions, in the following order: 
• fl uoxetine (Prozac) 
• duloxetine (Cymbalta) 
• escitalopram (Lexapro) 
• paroxetine (Paxil)
• venlafaxine (Effexor) 
• sertraline (Zoloft). 
Sertraline and escitalopram, the 
drugs shown to be most effective and 
acceptable in the Cipriani meta-analysis, 
accounted for 11.8% and 14.5% of the 
prescriptions, respectively. 
Antidepressants 
that are less 
effective and less 
acceptable than 
sertraline or 
escitalopram have 
been prescribed 
with greater 
frequency. 
C O N T I N U E D
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CAVEATS
❚  Meta-analysis looked only 
at acute treatment phase
The results of this study are limited to ini-
tial therapy as measured at 8 weeks. Lit-
tle long-term outcome data are available; 
response to initial therapy may not be a 
predictor of full remission or long-term 
success. Current guidelines suggest main-
tenance of the initial successful therapy, 
often with increasing intervals between 
visits, to prevent relapse.9
This study does not add new insight 
into long-term response rates. Nor does 
it deal with choice of a replacement or 
second antidepressant for nonresponders 
or those who cannot tolerate the initial 
drug.
What’s more, the study covers drug 
treatment alone, which may not be the 
best initial treatment for depression. 
Psychotherapy, in the form of cogni-
tive behavioral therapy or interpersonal 
therapy, when available, is equally effec-
tive, has fewer potential physiologic side 
effects, and may produce longer-lasting 
results.10,11
❚  Little is known about 
study design
The authors of this study had access only 
to limited information about inclusion 
criteria and the composition of initial 
study populations or settings. There is 
a difference between a trial designed to 
evaluate the “effi cacy” of an intervention 
(“the benefi cial and harmful effects of an 
intervention under controlled circum-
stances”) and the “effectiveness” of an 
intervention (the “benefi cial and harmful 
effects of the intervention under usual 
circumstances”).12 It is not clear which 
of the 117 studies were effi cacy studies 
and which were effectiveness studies. 
This may limit the overall generalizabil-
ity of the study results to a primary care 
population. 
Studies included in this meta-analysis 
were selected exclusively from published 
literature. There is some evidence that 
there is a bias toward the publication 
of studies with positive results, which 
may have the effect of overstating the 
effectiveness of a given antidepressant.13 
However, we have no reason to believe 
that this bias would favor any particular 
drug. 
Most of the included studies were 
sponsored by drug companies. Notably, 
pharmaceutical companies have the op-
tion of continuing to conduct trials of 
medications until a study results in a pos-
itive fi nding for their medication, with no 
penalty for the suppression of equivocal 
or negative results (negative publication 
bias). Under current FDA guidelines, there 
is little transparency to the consumer as 
to how many trials have been undertaken 
and the direction of the results, published 
or unpublished.14
We doubt that either publication 
bias or the design and sponsorship of 
the studies included in this meta-analysis 
present signifi cant threats to the valid-
ity of these fi ndings over other sources 
upon which guidelines rely, given that 
these issues are common to much of the 
research on pharmacologic therapy. We 
also doubt that the compensation of the 
authors by pharmaceutical companies 
would bias the outcome of the study in 
this instance. One of the authors (TAF) 
received compensation from Pfi zer, the 
maker of Zoloft, which is also available 
as generic sertraline. None of the au-
thors received compensation from Forest 
Pharmaceuticals, the makers of Lexapro 
(escitalopram).
CHALLENGES TO IMPLEMENTATION
❚  No major barriers 
are anticipated 
Both sertraline and escitalopram are cov-
ered by most health insurers. As noted 
above, sertraline is available in generic 
formulation, and is therefore much less 
expensive than escitalopram. In a check 
of online drug prices, we found a prescrip-
tion for a 3-month supply of Lexapro 
(10 mg) to cost about $250; a 3-month 
supply of generic sertraline (100 mg) 
Response in 
the acute phase 
of treatment for 
major depression 
may not be 
predictive of 
long-term 
outcomes.
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from the same sources would cost approximately $35 
(www.pharmcychecker.com). Both Pfi zer, the maker 
of Zoloft, and Forest Pharmaceuticals, the maker of 
Lexapro, have patient assistance programs to make 
these medications available to low-income, uninsured 
patients. ■
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Osteoarthritis (OA) is the most common type of arthritis and 
a leading cause of pain and physical 
disability, especially in older indi-
viduals.1-3 Current treatment options 
emphasize lifestyle modifi cations, 
including diet and tailored exercise 
programs to reduce weight, if nec-
essary, and to maintain joint mo-
bility. However, almost all patients 
with symptoms require some form of 
pharmacologic intervention to man-
age those symptoms. Th is article will 
support the eff orts of primary care 
physicians to correctly diagnose their 
patients with OA and initiate an ef-
fective treatment plan that includes 
a combination of lifestyle modifi ca-
tions, weight management, physical 
therapy, and pharmacologic agents 
to eff ectively manage symptoms and 
improve joint mobility while ensur-
ing patient safety and quality of life.
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